BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 20495354)

  • 1. Combination effects of bortezomib with gemcitabine and EMAP II in experimental pancreatic cancer.
    Awasthi N; Schwarz MA; Schwarz RE
    Cancer Biol Ther; 2010 Jul; 10(1):99-107. PubMed ID: 20495354
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EMAP II-based antiangiogenic-antiendothelial in vivo combination therapy of pancreatic cancer.
    Schwarz RE; Awasthi N; Konduri S; Cafasso D; Schwarz MA
    Ann Surg Oncol; 2010 May; 17(5):1442-52. PubMed ID: 20041350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancing sorafenib-mediated sensitization to gemcitabine in experimental pancreatic cancer through EMAP II.
    Awasthi N; Zhang C; Hinz S; Schwarz MA; Schwarz RE
    J Exp Clin Cancer Res; 2013 Mar; 32(1):12. PubMed ID: 23497499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The efficacy of a novel, dual PI3K/mTOR inhibitor NVP-BEZ235 to enhance chemotherapy and antiangiogenic response in pancreatic cancer.
    Awasthi N; Yen PL; Schwarz MA; Schwarz RE
    J Cell Biochem; 2012 Mar; 113(3):784-91. PubMed ID: 22020918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of poly-mechanistic antiangiogenic combinations to enhance cytotoxic therapy response in pancreatic cancer.
    Awasthi N; Zhang C; Ruan W; Schwarz MA; Schwarz RE
    PLoS One; 2012; 7(6):e38477. PubMed ID: 22723862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An antiendothelial combination therapy strategy to increase survival in experimental pancreatic cancer.
    Schwarz RE; Konduri S; Awasthi N; Cafasso D; Schwarz MA
    Surgery; 2009 Aug; 146(2):241-9. PubMed ID: 19628080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhancing cytotoxic agent activity in experimental pancreatic cancer through EMAP II combination therapy.
    Awasthi N; Schwarz MA; Schwarz RE
    Cancer Chemother Pharmacol; 2011 Sep; 68(3):571-82. PubMed ID: 21110024
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BMS-754807, a small-molecule inhibitor of insulin-like growth factor-1 receptor/insulin receptor, enhances gemcitabine response in pancreatic cancer.
    Awasthi N; Zhang C; Ruan W; Schwarz MA; Schwarz RE
    Mol Cancer Ther; 2012 Dec; 11(12):2644-53. PubMed ID: 23047891
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor effects of EMAP II against pancreatic cancer through inhibition of fibronectin-dependent proliferation.
    Schwarz RE; Awasthi N; Konduri S; Caldwell L; Cafasso D; Schwarz MA
    Cancer Biol Ther; 2010 Apr; 9(8):632-9. PubMed ID: 20212356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proteasome inhibition activates epidermal growth factor receptor (EGFR) and EGFR-independent mitogenic kinase signaling pathways in pancreatic cancer cells.
    Sloss CM; Wang F; Liu R; Xia L; Houston M; Ljungman D; Palladino MA; Cusack JC
    Clin Cancer Res; 2008 Aug; 14(16):5116-23. PubMed ID: 18698029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resveratrol, a multitargeted agent, can enhance antitumor activity of gemcitabine in vitro and in orthotopic mouse model of human pancreatic cancer.
    Harikumar KB; Kunnumakkara AB; Sethi G; Diagaradjane P; Anand P; Pandey MK; Gelovani J; Krishnan S; Guha S; Aggarwal BB
    Int J Cancer; 2010 Jul; 127(2):257-68. PubMed ID: 19908231
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia.
    McDonald PC; Chafe SC; Brown WS; Saberi S; Swayampakula M; Venkateswaran G; Nemirovsky O; Gillespie JA; Karasinska JM; Kalloger SE; Supuran CT; Schaeffer DF; Bashashati A; Shah SP; Topham JT; Yapp DT; Li J; Renouf DJ; Stanger BZ; Dedhar S
    Gastroenterology; 2019 Sep; 157(3):823-837. PubMed ID: 31078621
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Leveraging combinatorial chemotherapy to improve outcomes in patients with pancreatic cancer.
    Koniaris LG; Jin X; Montero AJ; Zimmers TA
    Cancer Biol Ther; 2010 Jul; 10(1):108-9. PubMed ID: 20581450
    [No Abstract]   [Full Text] [Related]  

  • 14. Gemcitabine and CHK1 inhibition potentiate EGFR-directed radioimmunotherapy against pancreatic ductal adenocarcinoma.
    Al-Ejeh F; Pajic M; Shi W; Kalimutho M; Miranda M; Nagrial AM; Chou A; Biankin AV; Grimmond SM; ; Brown MP; Khanna KK
    Clin Cancer Res; 2014 Jun; 20(12):3187-97. PubMed ID: 24838526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NEMO peptide inhibits the growth of pancreatic ductal adenocarcinoma by blocking NF-κB activation.
    Zhuang Z; Li H; Lee H; Aguilar M; Gocho T; Ju H; Iida T; Ling J; Fu J; Wu M; Sun Y; Lu Y; Chiao PJ
    Cancer Lett; 2017 Dec; 411():44-56. PubMed ID: 28951128
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Altered Gemcitabine and Nab-paclitaxel Scheduling Improves Therapeutic Efficacy Compared with Standard Concurrent Treatment in Preclinical Models of Pancreatic Cancer.
    Wolfe AR; Robb R; Hegazi A; Abushahin L; Yang L; Shyu DL; Trevino JG; Cruz-Monserrate Z; Jacob JR; Palanichamy K; Chakravarti A; Williams TM
    Clin Cancer Res; 2021 Jan; 27(2):554-565. PubMed ID: 33087331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo therapy of local tumor progression by targeting vascular endothelium with EMAP-II.
    Schwarz RE; Schwarz MA
    J Surg Res; 2004 Jul; 120(1):64-72. PubMed ID: 15172191
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin 35 Expression Correlates With Microvessel Density in Pancreatic Ductal Adenocarcinoma, Recruits Monocytes, and Promotes Growth and Angiogenesis of Xenograft Tumors in Mice.
    Huang C; Li Z; Li N; Li Y; Chang A; Zhao T; Wang X; Wang H; Gao S; Yang S; Hao J; Ren H
    Gastroenterology; 2018 Feb; 154(3):675-688. PubMed ID: 28989066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumour activity of sunitinib in combination with gemcitabine in experimental pancreatic cancer.
    Awasthi N; Schwarz MA; Schwarz RE
    HPB (Oxford); 2011 Sep; 13(9):597-604. PubMed ID: 21843259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer.
    Nagathihalli NS; Castellanos JA; Shi C; Beesetty Y; Reyzer ML; Caprioli R; Chen X; Walsh AJ; Skala MC; Moses HL; Merchant NB
    Gastroenterology; 2015 Dec; 149(7):1932-1943.e9. PubMed ID: 26255562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.